Kidney Disease: Improving Global Outcomes has named Wolfgang C. Winkelmayer, MD, as co-chair of the organization. Winkelmayer is a Professor of Medicine, and the chair of the section of Nephrology at Baylor College of Medicine in Houston. He has served as a KDIGO Executive Committee member since 2015.

Winkelmayer is a native of Vienna, Austria where he earned his MD.. degree and went through internal medicine residency and nephrology fellowship. He subsequently earned MPH. and ScD. degrees in health policy and management from Harvard University and served on the faculty of Harvard Medical School at Brigham and Women’s Hospital for eight years. Starting in 2009, he spent five years on the faculty of Stanford University in Palo Alto, California where he was Director of Clinical Research in Nephrology. He joined Baylor College of Medicine in 2014, where is remains an active clinician and prolific clinical investigator. He is also an associate editor for Nephrology for the Journal of the American Medical Association and a Co-Editor of the American Journal of Kidney Diseases and serves on numerous editorial boards.

Winkelmayer succeeds Bert Kasiske of the University of Minnesota in Minneapolis, who served as KDIGO co-chair for six years.

New executive committee members

Four new members of the KDIGO Executive Committee have been recruited from the global nephrology community:

  • Dr. Ali Abu-Alfa of Lebanon
  • Dr. Jürgen Floege of Germany
  • Dr. Ziad Massy of France
  • Dr. Zhi-Hong Liu of China

These new members add to KDIGO’s volunteer leadership expertise in treatment, research and teaching. They will join the continuing members of the Executive Committee:

  • Dr. Olivier Devuyst of Switzerland
  • Dr. Andrew Levey of the United States
  • Dr. Roberto Pecoits-Filho of Brazil
  • Dr. Angela Wang of Hong Kong
  • Dr. Brian Pereira of the United States
  • Dr. Yusuke Tsukamoto of Japan
  • Dr. Christoph Wanner of Germany

KDIGO’s work plan for 2016 includes publishing a guideline on the Care of the Living Kidney Donor, launching a new guideline on Transplant Candidate Selection, and updating three guidelines on Mineral and Bone Disorder, Hepatitis C, and Blood Pressure Management. KDIGO will also hold Controversies Conferences on Common Elements in Uncommon Kidney Diseases, Challenges in Clinical Trials in Nephrology, and on the Transition from Stage 4 to Stage 5 CKD. Additionally, KDIGO will launch a series of Controversies Conferences on the Kidney, Heart, and Vasculature; the inaugural meeting will focus on the role of kidney function in the incidence and treatment of heart rhythm disorders. KDIGO will also continue to hold Clinical Practice Conferences focused on implementation of KDIGO Guidelines and Controversies Conference conclusions around the world.